fzr Inhibitors
The chemical class of fzr inhibitors encompasses a diverse array of compounds that target fzr either directly or indirectly by influencing specific signaling pathways crucial for cell cycle regulation. RO-3306, an inhibitor of cyclin-dependent kinase 1 (CDK1), indirectly impacts fzr by disrupting CDK1-mediated fzr phosphorylation events, thus affecting fzr's regulatory role in the cell cycle. Similarly, S-Trityl-L-cysteine, a microtubule polymerization inhibitor, indirectly inhibits fzr by interfering with microtubule dynamics, crucial for fzr localization and function during cell cycle progression.
Roscovitine, a potent CDK inhibitor, and Nocodazole, a microtubule-depolymerizing agent, further exemplify fzr inhibition by disrupting the signaling pathways involving fzr. Purvalanol A, BI2536, and GW843682X showcase fzr inhibition through their respective targets: CDKs, polo-like kinase 1 (PLK1), and Aurora B kinase. Olomoucine and Flavopiridol, both CDK inhibitors, contribute to fzr inhibition by disrupting CDK-mediated fzr phosphorylation events. VX-680 (Tozasertib) and BI-6727 (Volasertib) target fzr indirectly by inhibiting Aurora kinases and PLK1, respectively. Lastly, AZD7762 inhibits fzr by targeting checkpoint kinases (CHK1 and CHK2), disrupting their role in regulating fzr phosphorylation events during the cell cycle. This comprehensive set of fzr inhibitors provides valuable tools for dissecting the intricate molecular mechanisms governing fzr activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
RO-3306 | 872573-93-8 | sc-358700 sc-358700A sc-358700B | 1 mg 5 mg 25 mg | $66.00 $163.00 $326.00 | 37 | |
RO-3306 is a potent and selective inhibitor of cyclin-dependent kinase 1 (CDK1), which is involved in cell cycle regulation. By inhibiting CDK1, RO-3306 can indirectly modulate fzr activity since fzr is a substrate of CDK1. The inhibition of CDK1 disrupts the phosphorylation of fzr, affecting its regulatory role in the cell cycle and contributing to fzr inhibition. | ||||||
S-Trityl-L-cysteine | 2799-07-7 | sc-202799 sc-202799A | 1 g 5 g | $32.00 $66.00 | 6 | |
S-Trityl-L-cysteine is a microtubule polymerization inhibitor. It interferes with microtubule dynamics, which can indirectly impact fzr as fzr interacts with microtubules during the cell cycle. Disruption of microtubule dynamics by S-Trityl-L-cysteine can influence fzr localization and function, leading to its inhibition. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a potent inhibitor of cyclin-dependent kinases (CDKs). Since fzr is regulated by CDKs, inhibition of CDKs by Roscovitine can indirectly lead to fzr inhibition. The disruption of CDK-mediated phosphorylation events involving fzr affects its activity in cell cycle progression and checkpoint control. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent that disrupts microtubule structure and dynamics. Given fzr's association with microtubules, the interference caused by Nocodazole can indirectly inhibit fzr by affecting its localization and interaction with microtubules during cell cycle regulation. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a selective CDK inhibitor that affects the cell cycle. By inhibiting CDKs, Purvalanol A indirectly modulates fzr as fzr is a substrate of CDKs. The disruption of CDK-mediated fzr phosphorylation events contributes to fzr inhibition, influencing its role in cell cycle progression and checkpoint control. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
BI2536 is a selective inhibitor of polo-like kinase 1 (PLK1), a key regulator of cell cycle progression. Given the interplay between PLK1 and fzr, BI2536 can indirectly impact fzr activity by disrupting PLK1-mediated fzr phosphorylation events. The inhibition of PLK1 interferes with fzr's function in cell cycle control, contributing to fzr inhibition. | ||||||
Polo-like Kinase Inhibitor III | 660868-91-7 | sc-203202 | 500 µg | $109.00 | 1 | |
This inhibitor is a potent and selective inhibitor of Aurora B kinase, a crucial player in cell cycle regulation. As fzr is a substrate of Aurora B kinase, inhibition of Aurora B by GW843682X can indirectly lead to fzr inhibition. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a cyclin-dependent kinase (CDK) inhibitor that affects cell cycle progression. Since fzr is regulated by CDKs, Olomoucine can indirectly modulate fzr by disrupting CDK-mediated fzr phosphorylation events. The inhibition of CDKs interferes with fzr's role in cell cycle control, contributing to fzr inhibition. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a broad-spectrum cyclin-dependent kinase (CDK) inhibitor. By inhibiting CDKs, Flavopiridol can indirectly modulate fzr as fzr is a substrate of CDKs. The disruption of CDK-mediated fzr phosphorylation events contributes to fzr inhibition, influencing its role in cell cycle progression and checkpoint control. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
VX-680, also known as Tozasertib, is a pan-aurora kinase inhibitor. As fzr is a substrate of Aurora kinases, inhibition of Aurora kinases by VX-680 can indirectly lead to fzr inhibition. The disruption of Aurora kinase-mediated fzr phosphorylation events affects fzr's function in cell cycle control, contributing to fzr inhibition. | ||||||